Form 4: Blueprint Medicines Director Sells Shares to Cover Tax Obligations

Jeffrey W. Albers, a director at Blueprint Medicines Corp, sold 11,033 shares of common stock on March 7, 2024, to cover tax withholding obligations.

Summary

• On March 7, 2024, Jeffrey W. Albers, a director of Blueprint Medicines Corp, sold 11,033 shares of common stock at a price of $90.69 per share.
• The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units.
• Following the transaction, Albers directly owns 165,017 shares of Blueprint Medicines Corp.
• Albers has granted a limited power of attorney to Tracey McCain, Melissa Masse, Ariel Hurley, and Michael Landsittel to handle SEC filings on his behalf.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a routine stock sale for tax purposes. It doesn't indicate any significant positive or negative sentiment.

Industry Context

Sales of shares by company insiders are a common occurrence, often related to compensation or personal financial planning. It is important to consider the context of the sale, such as the reason for the sale and the amount of stock the insider still holds, to determine its potential impact.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but is unlikely to be significant given the stated reason for the sale.

Key Dates